BioMarin Signs Fairview Specialty for Kuvan Distribution

BioMarin Pharmaceutical has selected Fairview Specialty Pharmacy to be a participating pharmacy in the specialty pharmacy limited distribution network for Kuvan tablets, a specific drug therapy approved for the treatment of phenylketonuria.

Kuvan (sapropterin dihydrochloride) was approved by the FDA in December 2007 and is now available through Fairview Specialty Pharmacy for patients who are prescribed this treatment by their physicians.

Kari Amundson, Fairview Specialty Pharmacy director, said: “We are pleased to be selected by BioMarin to launch this new drug therapy. This distributor agreement is critical to our growth strategy and our ability to provide comprehensive care to patients across the Midwest and at the University of Minnesota Medical Center, Fairview.”